The success of copyright’s blockbuster initially sparked a boom for the drug industry, but recent changes present a murky scenario for shareholders. Generic alternatives are reducing profits, and continued litigation https://larapumw093789.uzblog.net/the-blue-pill-and-pharma-a-risky-investment-54819550